Telah dikemas kini
Signs Memorandum of Understanding with Attwill
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year
Through Large Scale Lyophilization, Tableting and Coating
establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine.
AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement.
investors.vaxart.com/news-releases/news-release-details/vaxart-inc-signs-memorandum-understanding-attwill-medical
Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year
Through Large Scale Lyophilization, Tableting and Coating
establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine.
AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement.
investors.vaxart.com/news-releases/news-release-details/vaxart-inc-signs-memorandum-understanding-attwill-medical
Dagangan aktif
Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speedtoday announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
The study is designed to demonstrate the efficacy of Vaxart’s oral COVID-19 vaccine candidate.
finance.yahoo.com/news/vaxart-covid-19-vaccine-selected-120010175.html
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.